An oncological view on the blood-testis barrier

被引:143
作者
Bart, J
Groen, HJM
van der Graaf, WTA
Hollema, H
Hendrikse, NH
Vaalburg, W
Sleijfer, DT
de Vries, EGE
机构
[1] Univ Groningen Hosp, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Internal Med, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen Hosp, PET Ctr, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen Hosp, Dept Pathol, NL-9700 RB Groningen, Netherlands
关键词
D O I
10.1016/S1470-2045(02)00776-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The function of the blood-testis barrier is to protect germ cells from harmful influences; thus, it also impedes the delivery of chemotherapeutic drugs to the testis. The barrier has three components: first, a physicochemical barrier consisting of continuous capillaries, Sertoli cells in the tubular wall, connected together with narrow tight junctions, and a myoid-cell layer around the seminiferous tubule. Second, an efflux-pump barrier that contains P-glycoprotein in the luminal capillary endothelium and on the myoid-cell layer; and multidrug-resistance associated protein 1 located basolaterally on Sertoli cells. Third, an immunological barrier, consisting of Fas ligand on Sertoli cells. Inhibition of P-glycoprotein function offers the opportunity to increase the delivery of cytotoxic drugs to the testis. In the future, visualisation of function in the blood-testis barrier may also be helpful to identify groups of patients in whom testis conservation is safe or to select drugs that are less harmful to fertility.
引用
收藏
页码:357 / 363
页数:7
相关论文
共 78 条
  • [1] Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar)
    Advani, R
    Saba, HI
    Tallman, MS
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Davis, E
    Paietta, E
    Litchman, M
    Sikic, BI
    Greenberg, PL
    [J]. BLOOD, 1999, 93 (03) : 787 - 795
  • [2] Death receptors: Signaling and modulation
    Ashkenazi, A
    Dixit, VM
    [J]. SCIENCE, 1998, 281 (5381) : 1305 - 1308
  • [3] Baer MR, 1999, BLOOD, V94, p383A
  • [4] The blood-brain barrier and oncology: new insights into function and modulation
    Bart, J
    Groen, HJM
    Hendrikse, NH
    van der Graaf, WTA
    Vaalburg, W
    de Vries, EGE
    [J]. CANCER TREATMENT REVIEWS, 2000, 26 (06) : 449 - 462
  • [5] BART J, 2001, P ASCO, V20, pA73
  • [6] Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO
  • [7] 2-S
  • [8] IMMUNOHISTOCHEMICAL CHARACTERIZATION OF SEMINOMA AND ITS INFLAMMATORY CELL INFILTRATE
    BELL, DA
    FLOTTE, TJ
    BHAN, AK
    [J]. HUMAN PATHOLOGY, 1987, 18 (05) : 511 - 520
  • [9] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [10] EFFECT OF TREATMENT ON FERTILITY AND SEXUAL FUNCTION IN MALES WITH METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS OF TESTIS
    BRENNER, J
    VUGRIN, D
    WHITMORE, WF
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1985, 8 (02): : 178 - 182